Vanguard Capital Wealth Advisors Takes Position in Arrowhead Pharmaceuticals, Inc. $ARWR

Vanguard Capital Wealth Advisors acquired a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 11,285 shares of the biotechnology company’s stock, valued at approximately $389,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Royal Bank of Canada lifted its position in shares of Arrowhead Pharmaceuticals by 30.2% in the 1st quarter. Royal Bank of Canada now owns 45,239 shares of the biotechnology company’s stock worth $576,000 after purchasing an additional 10,496 shares during the period. AQR Capital Management LLC bought a new position in Arrowhead Pharmaceuticals in the first quarter worth approximately $514,000. Goldman Sachs Group Inc. lifted its holdings in Arrowhead Pharmaceuticals by 34.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock worth $22,189,000 after buying an additional 447,456 shares during the period. Empowered Funds LLC boosted its position in Arrowhead Pharmaceuticals by 6.9% during the 1st quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company’s stock valued at $194,000 after acquiring an additional 979 shares in the last quarter. Finally, Focus Partners Wealth increased its holdings in shares of Arrowhead Pharmaceuticals by 1,339.5% in the 1st quarter. Focus Partners Wealth now owns 16,252 shares of the biotechnology company’s stock valued at $207,000 after acquiring an additional 15,123 shares during the period. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals News Roundup

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright lifted near‑term and full‑year EPS forecasts (reducing the expected losses for FY2026 and FY2027) and raised its price target to $100 while keeping a “Buy” rating — this signals stronger expected financial performance and underpins upside expectations. Article Title
• Positive Sentiment: B. Riley raised its price target to $101 and maintained a “Buy” rating, implying roughly ~45% upside from the referenced $69.59 level — another institutional endorsement that can attract buyers. Benzinga
• Positive Sentiment: Piper Sandler highlighted Arrowhead’s pipeline and upcoming Phase III hypertriglyceridemia readout, and has recently lifted its target (reported up to $110), drawing attention to near‑term data that could move the stock significantly. InsiderMonkey

Arrowhead Pharmaceuticals Stock Performance

ARWR opened at $69.59 on Friday. The company has a market cap of $9.46 billion, a P/E ratio of -869.77 and a beta of 1.21. The company has a quick ratio of 4.86, a current ratio of 4.86 and a debt-to-equity ratio of 0.43. The firm’s 50-day moving average price is $61.90 and its 200-day moving average price is $39.60. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $9.57 and a 52-week high of $76.76.

Analyst Ratings Changes

ARWR has been the subject of a number of analyst reports. Morgan Stanley upped their price objective on Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 7th. Royal Bank Of Canada boosted their target price on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a report on Thursday, December 11th. Bank of America raised their price target on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday. Finally, HC Wainwright increased their target price on shares of Arrowhead Pharmaceuticals from $85.00 to $100.00 and gave the company a “buy” rating in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $81.67.

Insider Activity at Arrowhead Pharmaceuticals

In other news, CEO Christopher Richard Anzalone sold 130,000 shares of the business’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $68.85, for a total transaction of $8,950,500.00. Following the sale, the chief executive officer directly owned 3,971,255 shares of the company’s stock, valued at $273,420,906.75. The trade was a 3.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Patrick O’brien sold 49,493 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $63.11, for a total value of $3,123,503.23. Following the completion of the transaction, the chief operating officer directly owned 474,908 shares in the company, valued at approximately $29,971,443.88. The trade was a 9.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 510,836 shares of company stock worth $33,603,060. 4.30% of the stock is owned by company insiders.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.